1. China Stocks

  2. •

    Consumer durables

  3. •

    Electronics/Appliances
OneRobotics (Shenzhen) Co., Ltd. Class H

OneRobotics (Shenzhen) Co., Ltd. Class H

HHKEX:6600
41.96
HKD
-0.98
(-2.28%)
17.92BMarket Cap
Mar 24Next Earn
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.24
2.06
2.74
4.95
- -
Basic EPS, GAAP
-0.39
-0.07
-0.01
-0.14
- -
Free Cash Flow per Basic Share
-0.52
0.05
-0.25
0.5
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
0.94
0.88
0.89
7.47
7.47
Tangible Book Value per Share
0.93
0.86
0.84
7.33
7.33
Basic Weighted Avg Shares
222
222
222
182
222
Sales/Revenue/Turnover
275
457
610
901
- -
Operating Margin (%)
-31.15
-3.16
0.58
-4.44
- -
Depreciation Expense
14
17
22
27
- -
Net Income, GAAP
-87
-16
-3
-25
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
-31.68
-3.58
-0.5
-2.74
- -
Working Capital
186
163
168
1,673
1,673
LT Debt
24
41
55
142
142
Total Equity
209
196
198
1,658
1,658
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-8.09
-1.56
-2.66
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
ST Debt
46
25
LT Borrowings
61
95
LT Finance Leases
37
47
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
222
222
Market Capitalization
- -
16,104

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Total Current Assets
567
2,039
Cash, Cash Equivalents & STI
200
1,586
Accounts Receivable, Net
133
86
Inventories
203
229
Total Current Liabilities
282
365
Payables & Accruals
- -
- -
ST Debt
46
25
Deferred Revenue
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
739.3%
Free Cash Flow
- -
- -
-266.68%
Net Income, GAAP
- -
- -
702.73%
Sales/Revenue/Turnover
- -
- -
47.65%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
457
2024
- -
- -
610
2025
- -
- -
901

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.07
2024
- -
- -
-0.01
2025
- -
- -
-0.14

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Li Zhi Chen
Full Time Employees
644
Sector
Consumer durables
Industry
Electronics/Appliances
Address
Qiancheng Commercial Center Shenzhen GD China 518102
IPO Date
Dec 30, 2025
Website
woanhome.com
Similar Companies
GoPro, Inc. (NASDAQ:GPRO)
Arcelik A.S. (BIST:ARCLK)
Richtech Robotics Inc. (NASDAQ:RR)
Aditya Infotech Limited (NSE:CPPLUS)
Whirlpool Of India Limited (NSE:WHIRLPOOL)
LG Electronics India Limited (NSE:LGEINDIA)
Business
SciClone Pharmaceuticals (Holdings) Limited (6600.HK) develops and commercializes biopharmaceutical products focused on oncology and severe infectious diseases in China and internationally. Founded in 1990 and headquartered in Shanghai, China, the company offers a portfolio of marketed products including its proprietary Zadaxin (thymalfasin) for chronic hepatitis B treatment; in-licensed Zometa for bone metastases and hypercalcemia of malignancy; DANYELZA for relapsed/refractory high-risk neuroblastoma; Oravig, Angiomax, Endoxan, Holoxan, Cytosafe, Farlutal, Campto and Vizimpro for oncology and related indications; as well as pipeline candidates such as PT-112, RRx-001, PEN-866, ORSERDU, Vaborem, Vibativ and Omburtamab. It sells these proprietary, in-licensed and promoted products through distributors to hospitals and pharmacies, primarily targeting the Chinese market with operations emphasizing innovation-driven growth. Recent developments include a strategic partnership with Tigermed in December 2021 to accelerate clinical research and development of innovative drugs; accelerated transformation to an innovation-driven model following its 2021 Hong Kong listing; a solo take-private transaction in 2024 by GL Capital at approximately USD 1.5 billion market capitalization; and in 2025, a USD 240 million continuation vehicle led by Abu Dhabi Investment Authority (ADIA) advised by Rede Partners, enabling GL Capital to retain control while pursuing commercial scaling, pipeline advancement and selective business development in immunity, oncology and infectious diseases.